Madrigal Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-19.935; its P/E ratio is -10.64; Madrigal Pharmaceuticals is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-6.23. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -95.24M	$ -82.90M	$ -98.71M	$ -85.30M	$ -79.69M
EBITDA	$ -94.43M	$ -82.22M	$ -98.15M	$ -84.86M	$ -79.57M
Net Income Common Stockholders	$ -98.74M	$ -85.80M	$ -76.90M	$ -85.91M	$ -81.20M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 232.35M	$ 298.42M	$ 329.48M	$ 358.77M	$ 153.19M
Total Assets	$ 237.96M	$ 302.46M	$ 331.94M	$ 362.57M	$ 158.64M
Total Debt	$ 116.56M	$ 99.66M	$ 84.62M	$ 49.89M	$ 49.81M
Net Debt	$ -115.79M	$ -198.76M	$ -244.86M	$ -308.88M	$ -103.38M
Total Liabilities	$ 215.72M	$ 198.96M	$ 182.31M	$ 165.18M	$ 147.97M
Stockholders Equity	$ 22.25M	$ 103.86M	$ 149.69M	$ 197.39M	$ 10.67M
Cash Flow	-
Free Cash Flow	$ -85.26M	$ -75.38M	$ -84.10M	$ -58.54M	$ -59.10M
Operating Cash Flow	$ -84.92M	$ -75.31M	$ -84.07M	$ -58.52M	$ -59.07M
Investing Cash Flow	$ 50.20M	$ -3.73M	$ -186.86M	$ 66.39M	$ 65.14M
Financing Cash Flow	$ 19.58M	$ 42.93M	$ 52.69M	$ 264.34M	$ 0.00

Currency in USD

Madrigal Pharmaceuticals Earnings and Revenue History

Income Statement >

Madrigal Pharmaceuticals Debt to Assets

Balance Sheet >

Madrigal Pharmaceuticals Cash Flow

Cash Flow >

Madrigal Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing